+1 Recommend
2 collections
      • Record: found
      • Abstract: found
      • Poster: found
      Is Open Access

      Global Pandemic COVID-19 (2019-nCoV): Novel Deadliest Contagion

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Global pandemic cause by coronavirus has been reported in Wuhan, China; in late December 2019. Within time duration of few weeks, the newly identified virus designated as 2019-Novel Coronavirus (2019-nCoV) and it was declared by World Health Organization (WHO). At the time of late January 2020, WHO announced it as the international emergency outbreak because of the rapid spread and increases at the global level. There is no any preventive vaccine is present or any approved therapy/treatment for this viral emergency which is very infectious globally. Till the previous few decades, six strains of coronaviruses were found, but in Wuhan, China in December 2019, a totally new strain of coronavirus was spread across the city. Within few days, it was designated as the novel coronavirus abbreviated as 2019-nCoV by World Health Organization. The rate of virus progression is still not determined and that is why it is very difficult to find the patient zero which is very essential. Phylogenetic analysis of the virus specifies bat origin of 2019-nCoV, its transmission is airborne i.e. human to human, infected person can be identified having the primary symptoms which includes high fever, upper or lower respiratory tract infection. Its diagnosis at the molecular level includes Real-Time PCR for encoding genes for the internal transcribed RNA-dependent RNA polymerase and Spike protein receptor binding domain. It can be confirmed by the Sanger Sequencing including full genome analysis by Next Generation Sequencing, multiplex nucleic acid amplification and microarray based analysis. There are few mRNA vaccines which were developed by few Biotechnology companies, showing positive results against COVID-19 and it is there in 4th phase clinical trial which possibly be the first vaccine available in the market in between mid-2021.

          Related collections

          Author and article information

          ScienceOpen Posters
          17 November 2020
          [1 ] Department of Molecular Biology and Genetic Engineering, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara-144411, Punjab, India.

          This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

          All data generated or analysed during this study are included in this published article (and its supplementary information files).

          Medicine, Life sciences

          2019-nCoV, Transmission of Corona Virus, Scientific Classification, mRNA Vaccine, Diagnosis of Corona Virus, Global Pandemic, Novel Deadliest Contagion, Novel Corona Virus


          Comment on this article